drugset / Trial / NCT01666691
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly subcutaneous injections for 12 weeks.
Timeline
- Start
- 2012-08
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Beloranib | Small molecule | 0.3 mg | Subcutaneous |
| Subject | Beloranib | Small molecule | 0.6 mg | Subcutaneous |
| Subject | Beloranib | Small molecule | 1.2 mg | Subcutaneous |
| Subject | Beloranib | Small molecule | 2.4 mg | Subcutaneous |
| Subject | Beloranib | Small molecule | 3.2 mg | Subcutaneous |